Vaccines
What's holding back adult vaccination in the US?
A national survey of healthcare professionals found that patient hesitancy, access challenges and health system-level barriers are limiting adult vaccination rates in the US.
Behind the science US edition
Investors
We announced our second quarter 2026 results on Tuesday, 28 July.
Press releases
- Jemperli (dostarlimab-gxly) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
- Blenrep assigned permanent billing code, supporting timely access for patients with relapsed/refractory multiple myeloma
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSK Global links
Visit our Global site for additional features